Cargando…
The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124444/ https://www.ncbi.nlm.nih.gov/pubmed/30214296 http://dx.doi.org/10.2147/CMAR.S166468 |
_version_ | 1783353027941367808 |
---|---|
author | Schuurhuizen, Claudia SEW Verheul, Henk MW Braamse, Annemarie MJ Buffart, Laurien M Bloemendal, Haiko J Dekker, Joost Konings, Inge RHM |
author_facet | Schuurhuizen, Claudia SEW Verheul, Henk MW Braamse, Annemarie MJ Buffart, Laurien M Bloemendal, Haiko J Dekker, Joost Konings, Inge RHM |
author_sort | Schuurhuizen, Claudia SEW |
collection | PubMed |
description | BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether, in patients with metastatic colorectal cancer receiving first-line chemotherapy, cumulative toxicity comprising all grades of AEs is more predictive for QOL than cumulative toxicity due to only high-grade AEs. METHODS: One hundred and five patients starting treatment completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) questionnaire at baseline and 10 weeks. AEs, clinical outcomes, and demographics were retrieved from patient records. Cumulative toxicity scores were calculated in three ways: total number of high-grade AEs, total number of all-grade AEs, and total number of AEs multiplied by their grade (the severity score). Relations between cumulative toxicity scores and QOL were studied using multivariable linear regression analyses. RESULTS: The mean age of patients was 65 years, 68% were male, and 84% received oxaliplatin-based chemotherapy. A higher total number of AEs of all grades (B=−2.4, 95% CI=–3.9; −0.9) and the severity score (B=–1.4, 95% CI=–2.3; −0.5) were predictive for clinically relevant changes in physical QOL, whereas the total high-grade AEs was not. None of the cumulative toxicity scores were predictive for global QOL. CONCLUSION: Cumulative toxicity scores comprising all grades of AEs provide a better measure of treatment burden than a toxicity score comprising high-grade AEs only. Physical QOL seems to be more affected by AEs than global QOL. Our results emphasize that future clinical trials should present cumulative toxicity scores comprising all AE grades as well as physical QOL instead of global QOL. |
format | Online Article Text |
id | pubmed-6124444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61244442018-09-13 The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy Schuurhuizen, Claudia SEW Verheul, Henk MW Braamse, Annemarie MJ Buffart, Laurien M Bloemendal, Haiko J Dekker, Joost Konings, Inge RHM Cancer Manag Res Original Research BACKGROUND: Studies evaluating new systemic agents tend to report severe toxicities only, while the cumulative effect of multiple lower grade adverse events (AEs) may have an additional negative impact on patient quality of life (QOL). In the current observational cohort study, we evaluated whether, in patients with metastatic colorectal cancer receiving first-line chemotherapy, cumulative toxicity comprising all grades of AEs is more predictive for QOL than cumulative toxicity due to only high-grade AEs. METHODS: One hundred and five patients starting treatment completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) questionnaire at baseline and 10 weeks. AEs, clinical outcomes, and demographics were retrieved from patient records. Cumulative toxicity scores were calculated in three ways: total number of high-grade AEs, total number of all-grade AEs, and total number of AEs multiplied by their grade (the severity score). Relations between cumulative toxicity scores and QOL were studied using multivariable linear regression analyses. RESULTS: The mean age of patients was 65 years, 68% were male, and 84% received oxaliplatin-based chemotherapy. A higher total number of AEs of all grades (B=−2.4, 95% CI=–3.9; −0.9) and the severity score (B=–1.4, 95% CI=–2.3; −0.5) were predictive for clinically relevant changes in physical QOL, whereas the total high-grade AEs was not. None of the cumulative toxicity scores were predictive for global QOL. CONCLUSION: Cumulative toxicity scores comprising all grades of AEs provide a better measure of treatment burden than a toxicity score comprising high-grade AEs only. Physical QOL seems to be more affected by AEs than global QOL. Our results emphasize that future clinical trials should present cumulative toxicity scores comprising all AE grades as well as physical QOL instead of global QOL. Dove Medical Press 2018-08-29 /pmc/articles/PMC6124444/ /pubmed/30214296 http://dx.doi.org/10.2147/CMAR.S166468 Text en © 2018 Schuurhuizen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Schuurhuizen, Claudia SEW Verheul, Henk MW Braamse, Annemarie MJ Buffart, Laurien M Bloemendal, Haiko J Dekker, Joost Konings, Inge RHM The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title | The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title_full | The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title_fullStr | The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title_full_unstemmed | The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title_short | The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
title_sort | predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124444/ https://www.ncbi.nlm.nih.gov/pubmed/30214296 http://dx.doi.org/10.2147/CMAR.S166468 |
work_keys_str_mv | AT schuurhuizenclaudiasew thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT verheulhenkmw thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT braamseannemariemj thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT buffartlaurienm thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT bloemendalhaikoj thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT dekkerjoost thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT koningsingerhm thepredictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT schuurhuizenclaudiasew predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT verheulhenkmw predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT braamseannemariemj predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT buffartlaurienm predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT bloemendalhaikoj predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT dekkerjoost predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy AT koningsingerhm predictivevalueofcumulativetoxicityforqualityoflifeinpatientswithmetastaticcolorectalcancerduringfirstlinepalliativechemotherapy |